RE:RE:RE:So what is next week PR? Star, here is as much as is available for recent international sales in 2023
In the first quarter ended March 31, 2023 International medical cannabis sales amounted to CA$1.8 million, up from CA$1.3 million in the first quarter last year.
- CA$51,000 in Australia.
- CA$1.2 million in Germany.
- CA$575,000 in other, unspecified places.
Followed by a huge jump in Austrailia in Q2
"International Medical revenue in Q2 2023 was $3.0M versus $0.9M in Q2 2022 and $1.8M in Q1 2023 representing a 249% and 66% growth respectively. The growth of International Medical was largely driven by the integration of VIVO's Australian business, Beacon Medical Australia." Now add Brazil to the mix as Labs hopes to send additional supply in Q1, 2024
On another note, as s1i mentioned, there is a lot going on behind the scenes.
"MediPharm Labs is the first company in Canada to go through an in-depth Active Pharmaceutical Ingredient (API) filing review with the FDA for a natural cannabinoid molecule, according to the FDA inspection and foreign manufacturing site databases.The Company is also the first THC-touching facility in North America to have an on-site FDA inspection, according to the FDA inspection and foreign manufacturing site databases"
"Began in-depth correspondence with the United States Food and Drug Administration (the "FDA") in February 2023 regarding recent on-site inspection related to Drug Master File being submitted as part of an Abbreviated New Drug Application (ANDA) submission by an international pharmaceutical partner." "In March 2023, one of MediPharm's US-based academic research partners received FDA approval of an Investigational New Drug (IND), which is expected to allow for participant dosing to begin in the coming months.(2)"